Prevention of host-to-host transmission by SARS-CoV-2 vaccines

被引：64
作者：
Mostaghimi, Darius [1 ,2 ]
Valdez, Caroline N. [2 ]
Larson, Haleigh [2 ,4 ]
Kalinich, Chaney C. [2 ,3 ]
Iwasaki, Akiko [1 ,2 ,3 ,5 ]
机构：
[1] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, New Haven, CT USA
[3] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA
[4] Yale New Haven Hosp, Dept Cardiac Surg, 20 York St, New Haven, CT 06504 USA
[5] Howard Hughes Med Inst, Chevy Chase, MD USA
来源：
LANCET INFECTIOUS DISEASES | 2022年 / 22卷 / 02期
关键词：
PRACTICES INTERIM RECOMMENDATION; CORONAVIRUS DISEASE 2019; COVID-19; VACCINE; ADVISORY-COMMITTEE; UNITED-STATES; INFECTION; PROTECTS; EFFICACY;
D O I：
10.1016/S1473-3099(21)00472-2
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
As the number of individuals vaccinated against SARS-CoV-2 rises worldwide, population-level data regarding the vaccines' ability to reduce infection are being generated. Randomised trials have shown that these vaccines dramatically reduce symptomatic COVID-19; however, less is known about their effects on transmission between individuals. The natural course of infection with SARS-CoV-2 involves infection of the respiratory epithelia and replication within the mucosa to sufficient viral titres for transmission via aerosol particles and droplets. Here we discuss the available data on the existing, approved SARS-CoV-2 vaccines' capacity to reduce transmissibility by reducing primary infection, viral replication, capacity for transmission, and symptomaticity. The potential for mucosal-targeted SARS-CoV-2 vaccine strategies to more effectively limit transmission than intramuscular vaccines is considered with regard to known immunological mechanisms. Finally, we enumerate the population-level effects of approved vaccines on transmission through observational studies following clinical trials and vaccine distribution in real-world settings.
引用
收藏
页码：E52 / E58
页数：7
相关论文
共 74 条
[71]   DNA vaccine protection against SARS-CoV-2 in rhesus macaques [J].
Yu, Jingyou ;
Tostanoski, Lisa H. ;
Peter, Lauren ;
Mercado, Noe B. ;
McMahan, Katherine ;
Mahrokhian, Shant H. ;
Nkolola, Joseph P. ;
Liu, Jinyan ;
Li, Zhenfeng ;
Chandrashekar, Abishek ;
Martinez, David R. ;
Loos, Carolin ;
Atyeo, Caroline ;
Fischinger, Stephanie ;
Burke, John S. ;
Slein, Matthew D. ;
Chen, Yuezhou ;
Zuiani, Adam ;
Lelis, Felipe J. N. ;
Travers, Meghan ;
Habibi, Shaghayegh ;
Pessaint, Laurent ;
Van Ry, Alex ;
Blade, Kelvin ;
Brown, Renita ;
Cook, Anthony ;
Finneyfrock, Brad ;
Dodson, Alan ;
Teow, Elyse ;
Velasco, Jason ;
Zahn, Roland ;
Wegmann, Frank ;
Bondzie, Esther A. ;
Dagotto, Gabriel ;
Gebre, Makda S. ;
He, Xuan ;
Jacob-Dolan, Catherine ;
Kirilova, Marinela ;
Kordana, Nicole ;
Lin, Zijin ;
Maxfield, Lori F. ;
Nampanya, Felix ;
Nityanandam, Ramya ;
Ventura, John D. ;
Wan, Huahua ;
Cai, Yongfei ;
Chen, Bing ;
Schmidt, Aaron G. ;
Wesemann, Duane R. ;
Baric, Ralph S. .
SCIENCE, 2020, 369 (6505) :806-+
[72]   Current prospects and future challenges for nasal vaccine delivery [J].
Yusuf, Helmy ;
Kett, Vicky .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (01) :34-45
[73]   BNT162b2 Vaccine Effectiveness in Preventing Asymptomatic Infection With SARS-CoV-2 Virus: A Nationwide Historical Cohort Study [J].
Zacay, Galia ;
Shasha, David ;
Bareket, Ronen ;
Kadim, Itai ;
Hershkowitz Sikron, Fabienne ;
Tsamir, Judith ;
Mossinson, David ;
Heymann, Anthony D. .
OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (06)
[74]  
Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI [10.1056/NEJMoa2001017, 10.1172/JCI89857]
12345678